Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7297623 | 0.91 | TSHR (0.40) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL2139429 | 0.85 | ALDH1A1 (0.43) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL1454783 | 0.85 | — | — | |
| SCHEMBL3250029 | 0.84 | TSHR (0.42) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL7295281 | 0.84 | TSHR (0.41) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL1506323 | 0.82 | LMNA (0.47) | LMNAALOX15MEN1CYP3A4KMT2A | |
| SCHEMBL2119049 | 0.81 | TSHR (0.40) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL815732 | 0.81 | TSHR (0.52) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL20526052 | 0.79 | ALOX15 (0.43) | TSHRALDH1A1LMNAALOX15MEN1 | |
| SCHEMBL5986460 | 0.79 | LMNA (0.33) | ALDH1A1LMNAALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2444401-B1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO (JP) | 2014-09-03 | — | — | EP | disclosed |
| US-8569504-B2 | Imidazopyridine compound | ONO PHARMACEUTICAL CO., LTD. (JP) | 2013-10-29 | — | — | US | disclosed |
| EP-2444401-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO Pharmaceutical Co., Ltd. (JP) | 2012-04-25 | — | — | EP | disclosed |
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | ONO PHARMACEUTICAL CO., LTD. (JP) | 2012-04-19 | — | — | US | disclosed |
| EP-0693284-A1 | PROSTACYCLIN-CONTAINING OLEAGINOUS OINTMENT | TEIJIN LIMITED (JP) | 1996-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094944-A1 | NOVEL IMIDAZOPYRIDINE COMPOUND | CMA1, ACE, ALPI | TSHR 4076/4885ALDH1A1 539/4885LMNA 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.